Table 2.
Gene Expression Subtypes Stratified by Race
| Subtype | No. of Samples* |
Adjusted OR† | 95% CI | Adjusted P | |
|---|---|---|---|---|---|
| African American | White | ||||
| PAM50 | |||||
| Luminal A | 27 | 247 | 0.39 | 0.25 to 0.60 | < .001 |
| Luminal B | 35 | 178 | 0.87 | 0.57 to 1.31 | .51 |
| HER2 | 24 | 84 | 1.32 | 0.81 to 2.16 | .27 |
| Basal-like | 62 | 132 | 2.70 | 1.85 to 3.95 | < .001 |
| Normal-like | 11 | 70 | 0.68 | 0.35 to 1.32 | .25 |
| TNBC | |||||
| Mesenchymal | 4 | 17 | 0.43 | 0.14 to 1.38 | .16 |
| Mesenchymal stem-like | 5 | 3 | 4.38 | 1.01 to 18.97 | .048 |
| Luminal androgen receptor | 0 | 4 | 0.13 | 0.01 to 3.08 | .21 |
| Immunomodulatory | 7 | 10 | 1.62 | 0.54 to 4.83 | .38 |
| Basal-like 1 | 7 | 4 | 6.21 | 1.53 to 25.25 | .01 |
| Basal-like 2 | 3 | 6 | 1.06 | 0.25 to 4.39 | .94 |
| Unsure | 1 | 14 | 0.19 | 0.03 to 1.08 | .06 |
NOTE. Odds ratios (ORs) adjusted for age and sex.
Abbreviations: HER2, human epidermal growth factor receptor 2; PAM50, 50-gene set predictor using predication analysis of microarray method; TNBC, triple-negative breast cancer.
*
For RNA sequencing data set.
†
African Americans compared with whites.